Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)

August 28, 2026 6:49 AM
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $41.00 price target on Roivant Sciences (NASDAQ: ROIV).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments